Press Release

    Statement from Michael Sapienza, CEO of the Colon Cancer Alliance, on FDA Approval of VARUBI Intravenous Administration

    October 26, 2017 (WASHINGTON)–VARUBI, a highly anticipated treatment for colorectal patients who suffer from delayed chemotherapy-induced nausea, has been approved by the Food and Drug Administration for delivery via one-time intravenous administration. This new way to administer VARUBI provides healthcare providers with flexibility to treat patients in a more individualized manner.

    VARUBI addresses delayed nausea that can arrive 24 to 120 hours after the start of chemotherapy. If nausea is not managed aggressively, it can lead to weight loss, dehydration, and hospitalization. Quality-of-life issues are incredibly important for patients and families dealing with colorectal cancer and chemotherapy. The approval of VARUBI is good step forward in addresses some of these concerns.

    For more information about VARUBI, please access:
    https://globenewswire.com/news-release/2017/10/25/1153687/0/en/TESARO-Announces-U-S-FDA-Approval-of-VARUBI-IV-for-Delayed-Nausea-and-Vomiting-Associated-With-Cancer-Chemotherapy.html

    Top resources

    View all resources
    A smiling woman with shoulder-length blonde hair stands in a stone archway, wearing a white tank top and sunglasses resting on her head. A blurred cityscape and greenery are visible in the background, suggesting a scenic viewpoint.

    Meredith’s legacy: A family’s mission to save lives

    After losing their sister Meredith to colorectal cancer, Kathryn and Abigail are turning grief into advocacy. Their powerful story highlights the urgent need for CRC awareness and action — especially among young adults who are facing rising rates of this disease.

    Last updated